Evidence map›Paper›PMID 29099756›Full record

ArticlePathogens (Basel, Switzerland)2017

Italian Physicians' Opinions on Rotavirus Vaccine Implementation.

Valentin Mita, Michele Arigliani, Laura Zaratti, Raffaele Arigliani, Elisabetta Franco

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Group A rotavirus surveillance before vaccine introduction in Italy, September 2014 to August 2017.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Valentin MitaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy. valentinmita@libero.it.
Michele AriglianiDepartment of Clinical and Experimental Medical Sciences, University Hospital of Udine, 33100 Udine, Italy. michelearigliani@gmail.com.ORCID 0000-0002-5366-4594
Laura ZarattiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy. laura.zaratti@uniroma2.it.
Raffaele AriglianiDepartment of Pediatrics, Università Politecnica delle Marche, 60126 Ancona, Italy. raffaelearigliani@gmail.com.
Elisabetta FrancoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy. franco@med.uniroma2.it.
University of Rome Tor Vergata · ITMarche Polytechnic University · ITUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rotavirus (RV) infection is the main cause of severe acute gastroenteritis (GE) in the pediatric population and has a major impact in both developing and industrialized countries. The reduction of severe RVGE cases, followed by death or hospitalization, is considered the main benefit of RV vaccination, even though its implementation often faces obstacles. In Italy, the recently approved National Immunization Plan aims to overcome the differences among regions, offering a universal free RV vaccination. The aim of the study was to evaluate the opinions on benefit and acceptability of RV vaccination related to the perception of the burden of RV disease. Data were collected from 108 physicians in 2015 by a questionnaire consisting of 12 questions; some answers were compared with those obtained with a similar tool in 2011. The majority of respondents (76.2%) was convinced of the benefit of the vaccine and 57.4% recommended it routinely, but more than half indicated a <25% adherence to RV vaccination among their patients. As the main reasons of vaccine refusal, skepticism about the vaccine (60.4%) and its cost (34.1%) were indicated. Our data confirm that more information and counselling are needed to increase RV vaccine coverage.

Indexed as

attitudesbeliefscoverageimmunizationintentionsknowledgenew vaccinesphysiciansrotavirus

Identifiers

PMID29099756
PMCPMC5750580
OpenAlexW2765261741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.